Epidemiological Aspects and Prognosis of Severe Pre-eclampsia in Bangui, Central African Republic

Norbert Richard Ngbale1,2, Christelle Edith Gaunetfet1, Alida Koïrokpi1, Simeon Matoulou1, Gertrude Kogboma-Gongo1, Kelly Mбано-Dede1, Abdoulaye Sepou1,2 and Alexandre Manirakiza2,3*

1 Hospital Communautaire de Bangui, Centrafrique, Central African Republic
2 The University of Bangui, Central African Republic
3 Institut Pasteur of Bangui, Epidemiology Service, Central African Republic

*Corresponding author: Alexandre Manirakiza, Institut Pasteur de Bangui, Epidemiology service, Central African Republic, E-mail: amanirak@yahoo.fr

Received date: January 16, 2019; Accepted date: February 21, 2019; Published date: February 28, 2019

Copyright: © 2019 Ngbale NR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: Severe preeclampsia is one of the most serious pathologies during pregnancy, with heavy morbidity and maternal-fetal mortality. The aim of our study was to help improve the management of severe preeclampsia.

Methods: We conducted a cross-sectional analytical study from 1st September 2015 to 30th August 2016, at the Obstetrics and Gynecology Department of the Hôpital communautaire of Bangui. The study population was pregnant and parturient patients with severe pre-eclampsia.

Results: Out of 4021 registered cases, 41 met the inclusion criteria, with a prevalence of 1.0%. The primiparous were the most represented (48.8%). Magnesium sulfate was the most used as an anticonvulsant (70.7%) and dihydralazine was the most used for the High Blood Pressure (HBP). The main complications of pre-eclampsia were eclampsia (29.3%) and acute renal failure (19.5%). Overall, maternal mortality was 9.8% and perinatal mortality was 31.7%.

Conclusion: The complications of severe preeclampsia are common in our study. The maternal and fetal prognosis remains a concern. Hence, we suggest early screening of pre-eclampsia symptoms during prenatal consultations to improve pregnancy outcome.

Keywords: Management; Prognosis; Severe preeclampsia

Introduction

Severe preeclampsia is one of the dreaded complications of High Blood Pressure (HBP) during pregnancy, with heavy morbidity and maternal-fetal morbidity. Worldwide, complications of HBP on pregnancy are the third leading cause of maternal mortality [1]. While the incidence of severe preeclampsia is low in Western Europe with 3% and 5% [2], in Africa, the frequency varies between 5% to 10% [3]. The diagnosis of preeclampsia is early in developed countries while in Africa the screening of such morbidity is often achieved at the stage of obstetric complications. Moreover, the weakness of health care implies its burden in developing countries [4].

In the Central African Republic, there is no published data about clinical aspects of severe preeclampsia. Hence, this study aimed to assess the extent and prognosis of severe preeclampsia in the Gynecology-Obstetrics Department of the Centre hospitals-Universitaire of Bangui, the Central African Republic.

Methods

This is a cross-sectional and analytical study, conducted from 1st September 2017 to 30th August 2018. All pregnant and parturient women who were hospitalized with symptoms of preeclampsia were included in this study after they gave oral consent for their participation. Severe preeclampsia was defined as follows:

- Pregnancy with more than 24 weeks of amenorrhea or a parturient with 1 severe high blood pressure at ≥ 160 mmHg for systolic blood pressure and/or ≥ 110 mmHg for diastolic blood pressure; 2 renal failure with oliguria (<500 ml/day) or azotemia > 135 μmol/l or proteinuria ≥ 3 g/day; 3 eclampsia or neurological disorders; 4 recurrent intrauterine growth retardation or fetal heart rate alteration.

Women with moderate preeclampsia were excluded from this study. A sample size of this study was exhaustive.

The treatment for the severe preeclampsia was symptomatic: injectable dihydralazine and clonidine, followed by methyl-dopa orally, in association with magnesium sulfate in case of eclampsia. This treatment was associated with the monitoring of the blood pressure, evaluating the maternal-fetal impact, extracting the fetus on a case-by-case based to the clinical evolution and finally, taking care of any complications that ensue.

Data collection was performed using a structured questionnaire. The data was entered and analyzed on the Epi-info version 3.5.4 database and analyzed with SPSS. Pearson’s Chi^2 comparison statistical tests were performed and the threshold of statistical significance was 5%.
Results

The total number of 4021 pregnant and parturient was recorded during the study period with 92 cases of preeclampsia (2.3% or 92/4021) among which 41 were severe cases (4.5% or 41/92).

The age average was 27 years (extremes: 16 and 41 years). The primiparous were the most frequent (53.6%).

Prenatal follow-up was achieved in 75.6% of the patients. The average number of hospitalization period of these patients was 10 days (Table 1).

The higher number of cases of pre-eclampsia was observed in our study during the period from January to March (Figure 1).

| Characteristics of Pregnant women | Number % |
|----------------------------------|-----------|
| Age (years)                      |           |
| 15 to 19                         | 6 (14.6)  |
| 20 to 24                         | 9 (21.9)  |
| 25 to 29                         | 10 (24.4) |
| 30 to 34                         | 9 (21.9)  |
| 35 to 39                         | 5 (12.2)  |
| 40+                              | 2 (4.9)   |
| Parity                           |           |
| Primiparous (childbirth)         | 22 (53.6) |
| Pauci pare (2 to 3 deliveries)   | 11 (26.8) |
| Multi-part (4 to 6 deliveries)   | 8 (19.6)  |
| Antenatal follow-up              |           |
| No antenatal follow-up           | 10 (23.4) |
| Prenatal follow-up               | 31 (75.6) |

Table 1: Socio-demographic profile of patients (age, parity, prenatal follow-up).

Eclampsia occurred in 12 (29.3%) patients and renal failure was observed in (8) 19.5% patients. Preterm delivery and acute fetal distress were the most observed complications with the proportion of 26.2% and 23.8%, respectively (Table 2).

The vaginal delivery was achieved for a proportion of 53% of patients. Perinatal and maternal deaths accounted for 28.6% and 9.7%, respectively.

The proportion of antenatal deaths was higher among parturient women who did not attend antenatal consultations (P=0.000136) (Table 3). The risk of seizure was lowest in parturient women who received preventive treatment with magnesium sulfate than in those without such treatment (P=0.004) (Table 4).

| Maternal complications (n=41) | Number (%) |
|------------------------------|------------|
| Eclampsia                    | 12 (29.3)  |
| Acute renal failure          | 8 (19.5)   |
| Delivery hemorrhage          | 4 (9.7)    |
| Placental retro hematoma     | 2 (4.8)    |
| Cerebrovascular accident     | 1 (2.6)    |
| Maternal death               | 4 (9.7)    |
| None                         | 10 (24.4)  |
| Fetal (n = 42) twin pregnancy|             |
| Acute fetal distress         | 11 (26.2)  |
| Inducted premature delivery  | 10 (23.8)  |
| Hypotrophy                   | 7 (16.7)   |
| Death                        | 12 (28.6)  |
| Eutrophic newborn            | 2 (4.7)    |

Table 2: Distribution of patients by maternal and fetal complications.

| Maternal death                  | Yes | No  | p-value |
|---------------------------------|-----|-----|---------|
| No Antenatal consultation       | 2   | 8   |         |
| Perinatal follow-up             | 2   | 29  | 0.24    |
| Perinatal death                 |     |     |         |
| Antenatal consultation          | 2   | 30  | 0.000136|
| No Antenatal consultation       | 7   | 3   |         |

Table 3: Association between prenatal consultation, maternal death, and perinatal death.
In our study, magnesium sulfate was used to prevent eclamptic seizures based on functional signs, and/or blood pressure as suggested by Roberts and collaborators [22], and based also to the formal recommendations experts in 2009 [23]; during convulsive seizures and afterward to prevent recurrence. The clinical evolution was satisfactory in this study. However, in Senegal, Cisse and collaborators did not found similar results with magnesium sulfate [4].

The maternal complications (eclampsia occurred and renal failure) found in our study are not almost comparable to those generally described elsewhere, with a relatively low frequency in developed countries [24] and in Senegal [4].

Acute fetal distress and premature delivery were the most observed fetal complications. In Congo, a frequency of 37.5% fetal distress and 43.75% premature delivery [2]. The maternal mortality recorded is mainly due to the occurrence eclampsia associated with the cerebral vascular accident. The maternal lethality found in this study was higher than that of other studies, with 7.3% previously in Bangui, 8.8% in Congo, 7.1% in Bamako, 5.3% in Guinea Conakry and 2.5% in France [25-29]. However, other studies reported relatively very higher maternal lethality frequencies: 17.9% in Côte d’Ivoire, 17.9% in Senegal, 15.7% in Burkina Faso, 21% in Gabon and more than 32%, in Madagascar [30-35]. This discrepancy could be explained by the deep differences in the quality of health care according to countries.

Conclusion

Severe pre-eclampsia is common in the Gynecology-Obstetrics Department of the Centre Hospitals-Universitaire of Bangui, the Central African Republic. This syndrome has resulted in a heavy burden in terms of maternal and fetal mortality and morbidity. Its management requires a multidisciplinary team with a well-codified protocol comprising the use of magnesium sulfate.

References

1. Organisation Mondiale de la Sante (2010) Mortalite maternelle. Aide-memoire N 348: 1-5.
2. Petit P, Top M, Chantreine F, Brichant JF, Dewandre PY, et al. (2009) Traitement de la pre-eclampsie severe : jusqu'où, et pour quels risques/ benefices ? Rev Med Liege 64: 620-25.
3. Perrin RX, Lokossou A, Denakpo J (2010) Prise en charge multidisciplinaire de la pre-eclampsie : les propositions pour l'Afrique Noire. J Gynecol Obstet Biol Reprod 39: 517-530.
4. Cisse CT, Thiama M, Diagne PM, Moreau JC. (2005) Prise en eclair en milieu Africain epidemiologique et pronostic au CHU de Dakar. Lettre Gynecol 301: 8-13.
5. Kartout L, Soummani A (2012) Les hypertonisons arterielles gravides/retrocesse/retrospective au service de gynecologie obstetrique B du CHU Mohamed VI de Marrak: Marrakech. 1-150.
6. Samake BM, Traore M, Goota L, Niani M, Traore Y, et al. (2011) Prise en charge des complications de la preeclampsie a Abidjan: les propositions pour l'Afrique Noire. J Gynecol Obstet Biol Reprod 39: 517-530.
7. Tchau BA, Salifou K, Hounponou FM, Hountovo S, ClobiliM, et al. (2012) Prise en charge de la preeclampsie/evosse dans l'Hopital Universitaire de Parakou (Benin). Soc Anesth Reanim Afr Noire franc 17: 1-17.
8. Coulibaly Klyna T (2014) Les complications de la preeclampsie en reanimation polyvalente du CHU de Cocody (Abidjan-RCI). Rev Afr Anesth Med Urgence 19: 1-7.
9. Merger R, Levy J, Melchior J (2001) Precis'd'Obstetrique. Paris Masson 6ème edition:1-359.

Table 4: Association between treatment received and the occurrence of eclampsia crisis.

| Treatment                        | Yes | No  | p-value |
|----------------------------------|-----|-----|---------|
| Magnesium sulphate in primary prevention | 2   | 20  | 0.0046  |
| Antihypertensive drug            | 10  | 9   |         |

In our study, magnesium sulfate was used to prevent eclamptic seizures based on functional signs, and/or blood pressure as suggested by Roberts and collaborators [22], and based also to the formal recommendations experts in 2009 [23]; during convulsive seizures and afterward to prevent recurrence. The clinical evolution was satisfactory in this study. However, in Senegal, Cisse and collaborators did not found similar results with magnesium sulfate [4].
10. Ngunga Nkondi M (2005) Pronostic maternel et fœtal au cours de la preeclampsie 1-79.
11. Adisso S, Lokosou A, Konongui D, Olowusalako A, Perrin RX, et al. (2002) Severe vasculo renal syndrome: epidemiology and Prognosis. J Soc Afr Gynecol Obstetrit 3: 1-6.
12. Kongnyuy E, Tjek P, Kouam L, Ngassa P, Wamba M, et al. (2004) Cesaerians section from preeclampsia-eclampsia at the University teaching Hospital (CHU) Yaounde. Clin Mother Health 6: 2.
13. Robillard P, Hulsey T, Penanin J (1994) Association of pregnancy induced hypertension with duration of sexual cohabitation before conception. Lancet 344: 973-975.
14. Vinatier D, Prolongean J, Dufour P (1995) Physiologie de la pre-eclampsie : place de l'immunologie. J Gynecol Obstet Biol Reprod 24: 387-399.
15. Moignet C, Diemunsch P, Pottecher T (2003) Anesthesie-reanimation et pre eclampsie. Conferences d'actualisation 387-406.
16. Sibai B (2003) Diagnosis and management of gestational hypertension and preeclampsia. J Obstet Gynecol 103: 181-92.
17. Duley L, Jhones S, Meher S (2013) Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rep 3: 144-149.
18. Cisse C, Fay-Dienne M, Ngabo D, Mbaye M, Diagne PM, et al. (2003) Indications therapeutiques et pronostic de l' eclampsie au CHU de Dakar. J Gynecol Obstet Biol Reprod 32: 239-245.
19. Lokossaou A, Talpara I, Sacca-Vehounkpe, Tognide M, Sacca P, et al. (2005) Essai clinique du sulfate de magnesium dans le PE severe et leclampsie en milieu Africain a Cotonou. J Soc Biol Clin 9: 46-53.
20. Roberts J, Villar J, Arulkumaran S (2002) Preventing and treatment eclampsie. J Biol Med 325: 609-610.
21. SFAR/CNGOF/ SFMP/ SFNN (2009) Recommandations formalisees d'experts communes.
22. Brouth Y, Ndjeundo PG, Tetchi YD, Amonkou AA, Pete Y, et al. (2008) Les eclampsies au centre hospitalier universitaire en Côte d'Ivoire : prise en charge, evolution et facteurs pronostics. Can J Anesth 55: 423-428.
23. Lankoande J, Toure B, Ouedraogo CM, Ouattara T, et al. (1998) Les eclampsies a la maternite du centre hospitalier national YalgadoOuedraogo de Ouagadougou (Burkina Faso): aspects epidemiologiques, cliniques et evolutifs. Med Afr Noire 45: 401-403.
24. Haddad B(2001)Priese in charge de la pre-eclampsie. Mise à jour en Gynecol Obstetrit 5-34.
25. Rakotomalohina H, Rajamonarison T, Randriamahavonjy R, Randrianampanalinarivo H (2009) Pourquoi l' eclampsie engendre une forte mortalite ? Une etude dans la maternite de Befelatanana. Revue d'Anesthesie-Reanimation et de Medecine d'urgence 1: 25-27.
26. Ben-salem F, Ben-salem K, Grati I, Arafouilc, Paleh R, et al. (2003) Facteurs de risques d' eclampsie : etude cas temoins. Annales Francaises d'Anesthesie et de Reanimation 22 : 865-869.